# OnCo record undifferentiated-pleomorphic-sarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "undifferentiated-pleomorphic-sarcoma" ;
  schema:name "Undifferentiated pleomorphic sarcoma (UPS)"@en ;
  schema:alternateName "UPS"@en, "Malignant fibrous histiocytoma (historic)"@en, "MFH"@en, "Pleomorphic sarcoma, not otherwise specified"@en ;
  schema:description "Undifferentiated pleomorphic sarcoma is the diagnosis for a high-grade soft tissue sarcoma whose cells show no recognisable line of differentiation. It is treated with surgery and radiotherapy, with doxorubicin-based chemotherapy for high-risk or spread disease, and it is one of the few sarcomas in which the immunotherapy drug pembrolizumab has clear activity."@en ;
  schema:url <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Undifferentiated_pleomorphic_sarcoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Undifferentiated_pleomorphic_sarcoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/extremity-soft-tissue-sarcoma/>, <https://onco.cc/cancers/liposarcoma/>, <https://onco.cc/cancers/myxofibrosarcoma/>, <https://onco.cc/cancers/leiomyosarcoma/>, <https://onco.cc/cancers/malignant-peripheral-nerve-sheath-tumour/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:trials <https://onco.cc/trials/sarc028/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014/>, <https://onco.cc/key-papers/paper-esmo-sts-guideline-gronchi-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-isg-sts-1001-gronchi-lancet-oncol-2017/>, <https://onco.cc/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/> ;
  onco:pipeline <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/trials/isg-sts-1001/> ;
  onco:standardOfCare <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/isg-sts-1001/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/terms/fnclcc-grade/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/trials/eortc-62012/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/trabectedin/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/checkpoint-inhibitor/> .